- ¥1tn
- ¥997bn
- ¥497bn
Brief: Kyowa Kirin Says License Agreement With Synaffix Expanded
Media: Japan's Kyowa Kirin eying $1 bln sale of pharma assets - Bloomberg News
Brief: MEI Pharma, Kyowa Kirin Report Clinical Data On Zandelisib At European Hematology Association 2022 Hybrid Congress
Brief: Mei Pharma And Kyowa Kirin Announce Acceptance Of Abstract For Presentation At American Society Of Clinical Oncology Annual Meeting 2022
Table: Kyowa Kirin -Q1 group results (IFRS)
Brief: Ardelyx Inks Agreement With Japanese Partner, Kyowa Kirin Co, To Amend License Agreement
MEI Pharma slumps on extended approval pathway for cancer drug
Table: Kyowa Kirin -2021 group results (IFRS)
Table: Kyowa Kirin -2021 parent results
Brief: Cumberland Pharmaceuticals Acquires Sancuso® From Kyowa Kirin North America
Brief: Mei Pharma And Kyowa Kirin Announce Data From Ongoing Global Phase 2 Tidal Study Evaluating Zandelisib As A Single Agent In Patients With Relapsed Or Refractory Follicular Lymphoma
Advisory: Wrongly coded alerts on Strength Master Fintness Tech withdrawn
Brief: MEI Pharma And Kyowa Kirin Receive Orphan Drug Designation For Follicular Lymphoma Treatment
Table: Kyowa Kirin -9-MTH group results (IFRS)
Brief: Kyowa Kirin North America Appoints Paula Soteropoulos to Board of Directors
Brief: Mei Pharma And Kyowa Kirin Announce First Patient Dosed In Phase 3 Study Of Zandelisib Plus Rituximab In Non Hodgkin's B-Cell Lymphoma
Table: Kyowa Kirin -6-MTH group results (IFRS)
Brief: Kyowa Kirin Provides Update On Application For Marketing Authorisation Of Istradefylline In Europe For The Treatment Of ‘Off’ Episodes In People Living With Parkinson’S
Brief: EMA Says CHMP Adopted Negative Opinion Recommending Refusal Of Marketing Authorisation For Nouryant